taNK Cells

About Brink Biologics

Brink Biologics leverages the NK-92 cell line to create standardized bioassays for the biopharmaceutical industry, offering a suite of engineered NK cell lines (aNK, haNK, taNK, etc.) under a licensing model. Its core business is providing 'killer assays' as tools for target validation, drug screening, potency testing, and immunogenicity assessment, primarily serving commercial and academic research clients. As an affiliate of the publicly traded ImmunityBio, it occupies a specialized niche in the contract research and development tools landscape, enabling more predictive and uniform cell-based testing for oncology and immunology therapeutics.

Therapeutic Areas